Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa.

Some Medicare Part D plans did not cover authorized generic versions of pricey hepatitis C drugs, with rebates likely to blame, an OIG report found.

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several ...

The authorized generics, announced amid HCV product pricing pressures, will cost $24,000 - less than one-third the branded drugs' prices - to reflect discounts given to payers.

Gilead Sciences said Monday it will launch generic versions of Harvoni and Epclusa, its top-selling hepatitis C drugs. Gilead will sell its chronic hepatitis C generics at a $24,000 list price for ...

BARCELONA — Generic direct-acting antivirals for hepatitis C virus infection presented a similar biochemical makeup and sustained virological response rate in an Australian study, according to a ...